Novel ADHD Therapy More Tolerable, Less Effective Than Current Treatment OptionsCentanafadine is a serotonin-norepinephrine-dopamine triple reuptake inhibitor. Read MoreCGRP Inhibitors Significantly Reduce Disability in MigraineStudy results add to the body of evidence demonstrating the efficacy of CGRP inhibitors for migraine treatment and prophylaxis. A look at how the genetics-based research field can become more fully integrated in all areas of health care going forward. Read MoreOptimizing Oncology Drug Interaction Alerts to Improve Patient SafetyAlthough excessive use can lead to fatigue, alerts can help proactively identify and prevent drug interactions. Read MoreASHP: Adalimumab Biosimilar Pipeline ReviewAt least 6 adalimumab biosimilars are set to launch in July 2023.

Source: Forbes June 12, 2023 22:07 UTC